Merck Chairman and CEO Robert Davis joins 'Mad Money' host Jim Cramer at the JPMorgan Healthcare Conference to talk recent ...

The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...

UPDATED: Thursday, Jan. 2 at 1:45 p.m. ET Shortly before the new year, Merck & Co. scored an approval for its potential blockbuster Winrevair in the U.K. The pulmonary arterial hypertension (PAH ...

Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, ...

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr.

With that acquisition, they got this drug called Winrevair. It is approved by the FDA, just this last year for an almost always fatal disease called pulmonary arterial hypertension.” Cramer ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the ...